Dr. Jason Kelly is the co-founder and CEO of Ginkgo Bioworks.  He took the company public and raised $1.6B in October 2021.  In December of 2022, Jason was selected to serve as the Chair of the US Government’s National Security Commission on Emerging Biotechnology which oversees how advancements in emerging biotechnology and related technologies will shape current and future activities of the US Department of Defense.

Ginkgo has built a 1000+ person, 300,000 sqft facility that is available as a service similar to cloud computing but for generating data for cell engineering.  Customers use this facility for RNA drug discovery, enzyme engineering, AAV manufacturing optimization, and more.  Prior to Ginkgo, Jason received B.S. degrees in Chemical Engineering and Biology and a PhD in Biological Engineering all from MIT.